Is Sermorelin Legal in Colorado?
See the public record for Sermorelin
At a glance
- FDA approval / None. Geref's approvals were withdrawn effective June 18, 2009 [1]
- Sold today / Compounded sermorelin, which FDA has not approved [4]
- Safety-risk page / Sermorelin is not listed (content dated 04/22/2026) [5]
- Outsourcing-facility list / Sermorelin acetate is category 1, under evaluation (updated March 21, 2025) [2]
- State-licensed pharmacy list / Sermorelin appears in no category (updated May 14, 2026) [3]
- Sport / Prohibited at all times by WADA [6][7]
What is sermorelin's federal status?
Sermorelin acetate was approved twice, both times as Geref (EMD Serono). NDA 019863, a 0.05 mg/ampule product approved December 28, 1990, was a diagnostic test of the pituitary's ability to secrete growth hormone. NDA 020443, 0.5 mg and 1 mg vials approved September 26, 1997, was for treating idiopathic growth hormone deficiency in children with growth failure [1]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [1].
The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications; FDA withdrew both approvals effective June 18, 2009. In March 2013 FDA determined Geref was not withdrawn from sale for reasons of safety or effectiveness [1][8].
That leaves compounding. Sermorelin products sold in the US today are compounded, not FDA-approved, and FDA does not review a compounded drug's safety, effectiveness or quality before it is marketed [4].
Where sermorelin sits on FDA's compounding lists
- It is not on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) [5].
- On the list of nominated bulk substances for outsourcing facilities, sermorelin acetate is category 1, under evaluation, and carries the list's symbol for substances that are components of FDA-approved drugs (updated March 21, 2025) [2].
- It appears in no category on the list for state-licensed pharmacies and physicians (updated May 14, 2026) [3], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].
What about Colorado specifically?
The material above is federal: approval history, FDA compounding lists and an HHS draft policy. None of it states a Colorado rule, so it cannot confirm whether a particular prescription or compounded product meets Colorado requirements.
Questions worth asking
What sermorelin is, and what it does
Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone, the shortest synthetic peptide with the full biological activity of GHRH. It is not growth hormone [10]. It acts on the pituitary's GHRH receptor to prompt release of the body's own growth hormone; after an intravenous dose in healthy men it was eliminated quickly, while growth hormone stayed raised for about 3 hours [10][11].
Sermorelin is banned in sport
WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, prohibited at all times, in and out of competition, as a non-Specified Substance; the 2027 List, in force January 1, 2027, names it too [6][7].
Frequently asked questions
Is sermorelin FDA-approved?
Is sermorelin legal in Colorado?
Why was Geref taken off the market?
What dose of sermorelin is approved?
Is sermorelin allowed in sport?
References
Show all 13 referencesHide references
- Federal Register :: Request Access.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- Official web page.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.